Store launching soon — browse the catalog and join the waitlist to be notified at launch.
✦USPS Priority Mail1–3 day delivery across the U.S.Free on orders over $200
Store launching soon — browse the catalog and join the waitlist to be notified at launch.
Your cart is empty
Senolytic Research Peptide
Also known as FOXO4 D-Retro-Inverso peptide
FOXO4-DRI is a 46-residue D-retro-inverso peptide studied in research as a senolytic agent that targets the interaction between FOXO4 and p53.
🚀 Launching soon — join the waitlist to be notified when this product is available.
This product is intended strictly for laboratory research use within Canada. It is not approved by Health Canada for the diagnosis, treatment, cure, or prevention of any disease. Not for human or veterinary use.
By purchasing, you confirm the material will be used solely for lawful research purposes in accordance with applicable Canadian regulations.
FOXO4-DRI is a 46-residue D-retro-inverso peptide studied in research as a senolytic agent that targets the interaction between FOXO4 and p53.
Experimental models examine selective removal of senescent cells in cell culture and in aged animals.
Third-party tested for purity, ID, quantity.
FOXO4-DRI is built from D-amino acids in reversed sequence, a retro-inverso design intended to preserve side-chain topology while resisting proteolysis. Research has focused on its disruption of the FOXO4-p53 interaction, which promotes nuclear exclusion of p53 and apoptosis in senescent cells while sparing proliferating cells.
Structural work has characterized the disordered p53 transactivation domain as the binding target. Preclinical studies span expanded human chondrocytes, aged Leydig cells, keloid fibroblasts, and vascular models.
FOXO4-DRI was designed from research showing that senescent cells depend on a FOXO4-p53 interaction to avoid apoptosis. Interfering with that interaction produced selective clearance of senescent cells in early models.
Subsequent work extended the peptide across tissue-specific senescence models and characterized its molecular target in more detail, alongside reports of context-dependent adverse outcomes.
Research into FOXO4-DRI focuses on selective senescent-cell clearance through disruption of the FOXO4-p53 axis. Frameworks evaluate p53 localization, apoptosis selectivity, and tissue-level outcomes of senolysis under controlled in vitro and preclinical conditions, including studies reporting harm in specific models.
No. Eppix Labs products are supplied exclusively for laboratory research. We do not provide dosing, administration, or usage guidance.
Each unit contains the labeled quantity of FOXO4-DRI. Independent third-party analysis verifies purity, identity, and net content per batch.
The unit contains only the research compound. Any laboratory materials required for reconstitution or experimental procedures must be sourced separately.
Duration depends entirely on research design, storage conditions, and laboratory protocol.
The disordered p53 transactivation domain is the target of FOXO4 and the senolytic compound FOXO4-DRI
PubMedSenolytic Peptide FOXO4-DRI Selectively Removes Senescent Cells From in vitro Expanded Human Chondrocytes
PubMedFOXO4-DRI alleviates age-related testosterone secretion insufficiency by targeting senescent Leydig cells in aged mice
PubMedFOXO4-DRI induces keloid senescent fibroblast apoptosis by promoting nuclear exclusion of upregulated p53-serine 15 phosphorylation
PubMedEliminating Senescent Cells Can Promote Pulmonary Hypertension Development and Progression
PubMedRelated
Pentadecapeptide studied for angiogenesis signaling, tissue repair pathways, and cellular regeneration research
From$50.00
$60.00
Small molecule studied for metabolic regulation, NAD pathways, and cellular energy signaling
From$40.00
Dual peptide complex studied for actin signaling, tissue regeneration pathways, and recovery system research
From$0.00
Oral peptide format studied for systemic repair signaling and gastrointestinal pathway research
$140.00
